Revenue is revenue. There is no logic to excluding some revenues. Milestone payments form a valid part of Neurens licensing income from Daybue.Either way, PE is irrelevant for a biotech in Neurens position.Telix currently has a PE of 154. Reata was bought for 4000x revenues and at a PE of -20. Ie they had no profits at all, just a massive loss.
The fact that a biotech in Neurens position is making good profits at a reasonable PE ratio is remarkable, and just reemphsises how undervalued Neuren is.
Revenue is revenue. There is no logic to excluding some...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |